Natera, Inc. (NTRA)
Market Cap | 23.20B |
Revenue (ttm) | 1.96B |
Net Income (ttm) | -253.24M |
Shares Out | 137.25M |
EPS (ttm) | -1.92 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 347,799 |
Open | 169.90 |
Previous Close | 169.34 |
Day's Range | 168.98 - 170.72 |
52-Week Range | 110.57 - 183.00 |
Beta | 1.76 |
Analysts | Strong Buy |
Price Target | 193.50 (+14.48%) |
Earnings Date | Aug 7, 2025 |
About NTRA
Natera, Inc., a diagnostics company, provides molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissu... [Read more]
Financial Performance
In 2024, Natera's revenue was $1.70 billion, an increase of 56.75% compared to the previous year's $1.08 billion. Losses were -$190.43 million, -56.20% less than in 2023.
Financial StatementsAnalyst Summary
According to 16 analysts, the average rating for NTRA stock is "Strong Buy." The 12-month stock price target is $193.5, which is an increase of 14.48% from the latest price.
News

Natera: A Buy As Positive Growth And Cashflow Outweigh Unprofitability
For my first rating of Natera, I called it a buy, while today's consensus seems to be between a hold and a strong buy. Both proven revenue growth and expected future growth outlooks are upside drivers...

Natera Provides Update on Patent Litigation with NeoGenomics
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today provided an update regarding its intellectual property litigation with NeoGe...

Signatera™ Test Selected for NRG-Sponsored Phase III ARCHER Trial in Bladder Cancer
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the activation of the NRG Oncology trial, ARCHER (NRG-GU015), a ra...

Natera to Present Signatera™ Data at the IASLC World Conference on Lung Cancer
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will present new data at the 2025 International Associatio...

Natera Technology Featured in 300+ Peer-Reviewed Publications, Underscoring Scientific Leadership in Precision Medicine
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing and precision medicine, today announced the publication of more than 300 peer-reviewed papers feat...

Natera Launches Proprietary AI Foundation Models to Accelerate Diagnostic and Therapeutic Innovation
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the launch of its proprietary AI foundation model platform. These ...

IMvigor011 Bladder Cancer Trial Achieves Positive Results, with Signatera™ Strongly Predicting Adjuvant Immunotherapy Benefit
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced positive topline results from the randomized, phase III IMvigor011...

Natera shares surge 17% after strong Q2 results and upgraded guidance
Shares of genetic testing company Natera (NASDAQ:NTRA) jumped sharply in morning trading, rising as much as 17% after the company reported better-than-expected second-quarter 2025 financial results an...

Natera, Inc. (NTRA) Q2 2025 Earnings Call Transcript
Natera, Inc. (NASDAQ:NTRA) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Alexey Aleshin - GM of Oncology and ECD & Chief Medical Officer Michael B. Brophy - Chief Fi...

Natera Reports Second Quarter 2025 Financial Results
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today reported its financial results for the second quarter ended June 30, 2025. R...

Natera Launches Fetal Focus™: A Noninvasive Prenatal Test for Inherited Conditions
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine, today announced the launch of Fetal Focus, a noninvasive prenatal ...

Natera Highlights Latest Prospera™ Data at WTC 2025; 16 Abstracts Including Five Oral Presentations
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will present several new datasets at the 2025 World Transp...

Natera to Report Its Second Quarter Results on August 7, 2025
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will release results for its second quarter ended June 30,...

Natera Announces Launch of ABCSG 61 (“TEODOR”), a Randomized Controlled Trial of Signatera™ in Early-Stage Breast Cancer
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the launch of the TEODOR trial (Neoadjuvant TrEatment Optimization...

PEDAL Study Successful, Shows Monitoring with Prospera™ Kidney Provides Accurate Prognosis of Long-Term Clinical Outcomes Following Rejection; Now Published in AJT
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing and precision medicine, today announced that the American Journal of Transplantation published fin...

Natera Presents Data at ESMO GI on its Tissue-Free Latitude™ MRD* Assay, Demonstrating Excellent Overall Performance in Colorectal Cancer
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced data from a colorectal cancer (CRC) study of its tissue-free Latit...

Natera to Present Clinical and Economic Utility of Signatera at ESMO GI, Highlights Innovations in MRD
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, announced new data that will be presented at the 2025 European Society for Medical...

Natera Announces Medicare Coverage for Signatera™ Genome
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that its genome-based Signatera MRD assay is now covered by Medica...

SignateraTM Genome Clinical Performance Highlighted at ASCO 2025
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, announced results from a large-scale pan-cancer study of its Signatera Genome assa...

Natera to Present over 25 Signatera™ Studies at 2025 ASCO Annual Meeting
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that data from more than 25 Signatera studies will be presented at...

Natera: The Clues In Q1 Earnings
Natera delivered stellar Q1 results, with revenue and EPS beating expectations, and strong volume growth, especially for its flagship Signatera product. Management sees significant upside for Signater...

Natera, Inc. (NTRA) Q1 2025 Earnings Call Transcript
Natera, Inc. (NTRA) Q1 2025 Earnings Call Transcript

Natera Reports First Quarter 2025 Financial Results
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today reported its financial results for the first quarter ended March 31, 2025. R...

Signatera Data From I-SPY 2 Trial to Be Presented at ESMO Breast Annual Congress
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, will present multiple datasets in breast cancer together with its collaborators at...

Prospera™ Heart Test with DQS Outperforms dd-cfDNA Percentage in Detecting Allograft Rejection, New AJT Publication Shows
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that the American Journal of Transplantation (AJT) published a new...